Literature DB >> 18026720

Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy.

D M Bowen1, A W Procter, D M A Mann, J S Snowden, M M Esiri, D Neary, P T Francis.   

Abstract

RATIONALE: Information is sparse on neurotransmitter deficiencies in frontotemporal dementia (FTD), in particular with reference to distinct histological subgroups and Alzheimer's disease (AD).
OBJECTIVES: To evaluate in FTD with the major histologies, and compare with AD and controls, neurotransmission indices, as these may help in developing treatment.
MATERIALS AND METHODS: Post-mortem grey matter from Brodmann Area 21, 9 and 7 of 51 brains was assayed for ten neurochemical parameters indexing neurotransmission. Repeated measures analyses of variance were carried out for each parameter comparing groups (FTD vs AD vs control) at each anatomical site.
RESULTS: In FTD only the indices of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid, serotonin (5-HT)(1A) and 5-HT(2A) receptors were significantly reduced from control values. Of the ten parameters only 5-HT(1A) receptors showed significant group x site interaction. This reflected disproportionate reduction in frontal and temporal compared to parietal cortex. In FTD three other receptors (muscarinic, M(1), N-methyl-D: -aspartate, NMDA, and kainate), choline acetyltransferase (ChAT) activity, 5-HT and 5-hydroxyindoleacetic acid content and 5-HT reuptake site values were not significantly reduced from control values. Only 5-HT, 5-HT reuptake site and ChAT values were significantly higher in FTD than AD. NMDA receptor and ChAT values were significantly reduced from control only in AD.
CONCLUSIONS: Neurochemical results in FTD indicate degeneration and loss of pyramidal neurones in frontotemporal neocortex, yet 5-HT afferents and 5-HT concentration, which are inhibitory on pyramidal neurones, were relatively preserved. This could lead to an excess of extraneural 5-HT causing underactivity of surviving pyramidal neurones. Pharmacotherapy with a 5-HT(1A) receptor antagonist may be indicated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18026720     DOI: 10.1007/s00213-007-0992-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  48 in total

1.  Distribution and properties of functional postsynaptic kainate receptors on neocortical layer V pyramidal neurons.

Authors:  Matthias Eder; Klaus Becker; Gerhard Rammes; Anja Schierloh; Shahnaz Christina Azad; Walter Zieglgänsberger; Hans-Ulrich Dodt
Journal:  J Neurosci       Date:  2003-07-23       Impact factor: 6.167

2.  'Traditional' pharmacotherapy may succeed in Alzheimer's disease.

Authors:  D M Bowen; P T Francis; M N Pangalos; P H Stephens; A W Procter; I P Chessell
Journal:  Trends Neurosci       Date:  1992-03       Impact factor: 13.837

3.  Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms.

Authors:  A W Procter; P T Francis; G C Stratmann; D M Bowen
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

4.  Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties.

Authors:  L E Schechter; D L Smith; S Rosenzweig-Lipson; S J Sukoff; L A Dawson; K Marquis; D Jones; M Piesla; T Andree; S Nawoschik; J A Harder; M D Womack; J Buccafusco; A V Terry; B Hoebel; P Rada; M Kelly; M Abou-Gharbia; J E Barrett; W Childers
Journal:  J Pharmacol Exp Ther       Date:  2005-06-10       Impact factor: 4.030

Review 5.  Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

6.  An electron microscopic study of the types and proportions of neurons in the cortex of the motor and visual areas of the cat and rat.

Authors:  D A Winfield; K C Gatter; T P Powell
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

7.  [3H]Kainic acid binding and choline acetyltransferase activity in Alzheimer's dementia.

Authors:  B R Pearce; D M Bowen
Journal:  Brain Res       Date:  1984-09-24       Impact factor: 3.252

8.  Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.

Authors:  J B Deakin; S Rahman; P J Nestor; J R Hodges; B J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-12-10       Impact factor: 4.530

9.  Altered serotonergic and cholinergic synaptic markers in Pick's disease.

Authors:  D L Sparks; W R Markesbery
Journal:  Arch Neurol       Date:  1991-08

10.  Dementia of frontal lobe type: neuropathology and immunohistochemistry.

Authors:  D M Mann; P W South; J S Snowden; D Neary
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

View more
  21 in total

1.  Interpersonal traits change as a function of disease type and severity in degenerative brain diseases.

Authors:  Marc Sollberger; John Neuhaus; Robin Ketelle; Christine M Stanley; Victoria Beckman; Matthew Growdon; Jung Jang; Bruce L Miller; Katherine P Rankin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-12-15       Impact factor: 10.154

Review 2.  Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.

Authors:  Geoffrey A Kerchner; Maria Carmela Tartaglia; Adam Boxer
Journal:  Expert Rev Neurother       Date:  2011-05       Impact factor: 4.618

Review 3.  Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.

Authors:  Gil D Rabinovici; Bruce L Miller
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 4.  Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.

Authors:  Gregory A Jicha
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

5.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

Review 6.  Diagnosis and management of behavioral variant frontotemporal dementia.

Authors:  Peter S Pressman; Bruce L Miller
Journal:  Biol Psychiatry       Date:  2013-11-13       Impact factor: 13.382

Review 7.  Review: disruption of the postsynaptic density in Alzheimer's disease and other neurodegenerative dementias.

Authors:  Yuesong Gong; Carol F Lippa
Journal:  Am J Alzheimers Dis Other Demen       Date:  2010-09-21       Impact factor: 2.035

8.  EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases.

Authors:  M Filippi; F Agosta; S Abrahams; F Fazekas; J Grosskreutz; S Kalra; J Kassubek; V Silani; M R Turner; J C Masdeu
Journal:  Eur J Neurol       Date:  2010-02-02       Impact factor: 6.089

9.  Kinetics of serotonin oxidation by heme-Aβ relevant to Alzheimer's disease.

Authors:  Soumya Mukherjee; Manas Seal; Somdatta Ghosh Dey
Journal:  J Biol Inorg Chem       Date:  2014-09-24       Impact factor: 3.358

Review 10.  Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.

Authors:  Rachel E Seltman; Brandy R Matthews
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.